{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:56:40Z","timestamp":1775609800469,"version":"3.50.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":1847,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"},{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In patients with multiple myeloma (MM) free light chain-induced cast nephropathy is a serious complication associated with poor survival. High-cut-off (HCO) hemodialysis can reduce the amount of serum free light chains (sFLC), but data on its impact on clinical outcome is limited and contradictory. To gain further insights we collected real world data from two major myeloma and nephrology centers in Austria and the Czech Republic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixty-one patients with MM and acute kidney injury, who were treated between 2011 and 2019 with HCO hemodialysis and bortezomib-based MM therapy, were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median number of HCO hemodialysis sessions was 11 (range 1\u201342). Median glomerular filtration rate at diagnosis was 7\u2009\u00b1\u20094.2\u00a0ml\/min\/1.73m2. sFLC after the first HCO hemodialysis decreased by 66.5% and by 89.2% at day 18. At 3 and 6 months, 26 (42.6%) and 30 (49.2%) of patients became dialysis-independent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The widely used strategy combining HCO hemodialysis and bortezomib-based antimyeloma treatment is dissatisfactory for half of the patients undergoing it and clearly in need of improvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-020-00939-2","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T05:02:25Z","timestamp":1609390945000},"page":"1263-1270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury"],"prefix":"10.1093","volume":"34","author":[{"given":"N.","family":"Steiner","sequence":"first","affiliation":[{"name":"Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Abdel Hamid","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kronbichler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Nephrology and Hypertension, Medical University of Innsbruck, Innsbruck, Austria 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Neuwirt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Nephrology and Hypertension, Medical University of Innsbruck, Innsbruck, Austria 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Myslivecek","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kollar","sequence":"additional","affiliation":[{"name":"Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic 4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lachmanova","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rysava","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Hruskova","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Spicka","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine and Hematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic 5"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Willenbacher","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Nachbaur","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Tesar","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Gunsilius","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria 1"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,31]]},"reference":[{"issue":"8","key":"2026012107473349700_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and treatment of renal failure in multiple myeloma","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia"},{"key":"2026012107473349700_CR2"},{"issue":"10","key":"2026012107473349700_CR3","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1093\/ndt\/gfr773","article-title":"Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis","volume":"27","author":"Hutchison","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"22","key":"2026012107473349700_CR4","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1182\/blood.V128.22.978.978","article-title":"Treatment of myeloma cast nephropathy (MCN): a randomized trial comparing intensive haemodialysis (HD) with high cut-off (HCO) or standard high-flux dialyzer in patients receiving a bortezomib-based regimen (the MYRE Study, by the Intergroupe Francophone","volume":"128","author":"Bridoux","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2026012107473349700_CR5","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(19)30014-6 30872075","article-title":"High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial","volume":"6","author":"Hutchison","year":"2019","journal-title":"Lancet Haematol"},{"key":"2026012107473349700_CR6"},{"issue":"6","key":"2026012107473349700_CR7","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1681\/ASN.2010080857","article-title":"Early reduction of serum-free light chains associates with renal recovery in myeloma kidney","volume":"22","author":"Hutchison","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2026012107473349700_CR8","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/ki.2008.108","article-title":"Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains","volume":"73","author":"Leung","year":"2008","journal-title":"Kidney Int"},{"key":"2026012107473349700_CR9","first-page":"5033","article-title":"Is renal impairment still a poor prognostic marker in myeloma care? A population based study including 1542 patients","volume":"120","author":"Uttervall","year":"2012","journal-title":"Am Soc Hematol"},{"issue":"1","key":"2026012107473349700_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/annonc\/mdt483","article-title":"Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents","volume":"25","author":"Dimopoulos","year":"2014","journal-title":"Ann Oncol"},{"key":"2026012107473349700_CR11"},{"issue":"4","key":"2026012107473349700_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2215\/CJN.04590908","article-title":"Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis","volume":"4","author":"Hutchison","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"30","key":"2026012107473349700_CR13","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1200\/JCO.2010.28.1238","article-title":"Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study","volume":"28","author":"Ludwig","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026012107473349700_CR14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3816\/CLM.2009.n.059","article-title":"Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors","volume":"9","author":"Dimopoulos","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"3","key":"2026012107473349700_CR15","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1681\/ASN.2006080821","article-title":"Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies","volume":"18","author":"Hutchison","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2026012107473349700_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0154993","article-title":"Impact of high-cut-off dialysis on renal recovery in dialysis-dependent multiple myeloma patients: Results from a case-control study","volume":"11","author":"Gerth","year":"2016","journal-title":"PLoS ONE"},{"issue":"21","key":"2026012107473349700_CR17","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1001\/jama.2017.17924","article-title":"Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial","volume":"318","author":"Bridoux","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"2026012107473349700_CR18","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2352-3026(19)30090-0","article-title":"High cutoff haemodialysis in myeloma cast nephropathy: further investigation is needed","volume":"6","author":"Bridoux","year":"2019","journal-title":"Lancet Haematol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00939-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-020-00939-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/34\/4\/1263\/66017921\/joneph_34_4_939.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00939-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/34\/4\/1263\/66017921\/joneph_34_4_939.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:47:39Z","timestamp":1768999659000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/34\/4\/1263\/8325948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12,31]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1007\/s40620-020-00939-2","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2020,12,31]]},"assertion":[{"value":"30 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval for data collection and publication was obtained from the Ethics Committee of the Medical University of Innsbruck (vote #1045\/2019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}